Get the Stockscreener App
0.3454
0.41%
0.0014
Pre-market:
.36
0.0146
+4.23%
Scienture Holdings Inc stock is traded at $0.3454, with a volume of 160.48K.
It is up +0.41% in the last 24 hours and down -4.06% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
See More
Previous Close:
$0.344
Open:
$0.351
24h Volume:
160.48K
Relative Volume:
0.32
Market Cap:
$14.03M
Revenue:
$656.60K
Net Income/Loss:
$-16.79M
P/E Ratio:
-0.3215
EPS:
-1.0743
Net Cash Flow:
$-11.12M
1W Performance:
-3.25%
1M Performance:
-4.06%
6M Performance:
-34.22%
1Y Performance:
-76.18%
1-Day Range:
$0.3355
$0.37
1-Week Range:
$0.3326
$0.3772
52-Week Range:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.3454 | 14.22M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.27 | 200.34M | 452.61M | -35.30M | 13.25M | -0.3863 |
PETS
Petmed Express Inc
|
1.96 | 41.03M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
1.45 | 10.81M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
3.13 | 7.79M | 14.03M | -76.59M | -13.73M | -41.45 |
Scienture Holdings Inc Stock (SCNX) Latest News
Price to sales forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to book forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX) - TradingView
SCNX Forecast — Price Target — Prediction for 2027 - TradingView
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Lift Shares - dars.gov.et
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Scienture stock rises after adding 12.5M covered lives for Arbli - Investing.com Nigeria
Scienture stock rises after adding 12.5M covered lives for Arbli By Investing.com - Investing.com Australia
Scienture (SCNX) Advances Commercialization of Arbli - GuruFocus
Scienture expands payor coverage for Arbli by 12.5M lives - Investing.com
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide - marketscreener.com
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Institutional Confidence - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX) - The Globe and Mail
Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected as Stock Declines 4.66%Dividend Earnings Report - newsline.com
Exclusive: Scienture expands coverage for opioid overdose treatment ahead of commercial launch - MSN
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Weakness Phase - newsline.com
Scienture Holdings (SCNX) Investor Relations, Earnings Summary & Outlook - Quartr
Scienture Holdings Inc. (SCNX) Rallies 6.43% to $0.38, Nears Key ResistanceRSI Oversold Picks - newsline.com
Scienture Holdings Inc at Small Cap Showcase & WTR Insights Conference Transcript - GuruFocus
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive MomentumCore Business Growth - newsline.com
Scienture’s naloxone nasal spray added to national health plan By Investing.com - Investing.com South Africa
Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team - marketscreener.com
Scienture’s naloxone nasal spray added to national health plan - Investing.com UK
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - The Manila Times
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch - Benzinga
Scienture Holdings (SCNX) Slides 5.26% as Stock Tests Key Support LevelsIchimoku TK Cross - newsline.com
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC - Corsicana Daily Sun
Scienture (SCNX) Secures Patent for Rezenopy Nasal Spray - GuruFocus
Scienture Secures US Patent Protection for Rezenopy Through 2041 - marketscreener.com
Scienture receives patent for naloxone nasal spray until 2041 By Investing.com - Investing.com South Africa
Scienture receives patent for naloxone nasal spray until 2041 - Investing.com
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 - The Manila Times
New high-dose naloxone nasal spray wins U.S. patent to 2041 - Stock Titan
Scienture Holdings, Inc. (SCNX) 8-K Filing: Director Changes and Company Details for May 2026 - Minichart
Scienture Holdings Announces CFO Resignation, Names Interim Successor - The Globe and Mail
ScientureEric Sherb resigns as CFO effective May 26, 2026 - marketscreener.com
Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026 - marketscreener.com
Scienture Holdings Inc Stock (SCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.38%
5.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):